ETSA winner Theranautilus heads to human trials; JSW One’s IPO plans
AI-summarised brief · reviewed before publication
Theranautilus, the winner of the 2026 ET Startup Awards, announced that its nanorobot platform will enter human clinical trials before the end of the year, marking the first Indian‑developed nanomedicine to reach this stage. The company, backed by Accel, aims to use the trials to validate its targeted drug‑delivery technology for cancer and other chronic diseases. In a separate development, steel‑maker JSW One disclosed plans to file a draft prospectus for a Rs 3,000‑crore initial public offering, seeking to list on Indian exchanges and raise capital for expansion of its integrated steel and renewable‑energy assets. Both announcements were highlighted in the Morning Dispatch newsletter, underscoring rapid innovation and capital‑raising activity in India’s tech‑driven sectors.
💡 Why It Matters
- · Theranautilus’ trial could position India as a pioneer in nanomedicine, while JSW One’s IPO signals aggressive funding for green steel ambitions.
